Asuragen | GenomeWeb

Asuragen

The firm, which makes both neurogenetic and oncology diagnostics, also provided updates on its market strategies and menu outlook.

The molecular test is now the first FDA-cleared assay to monitor treatment response and disease clearance in chronic myeloid leukemia patients.

When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.

Asuragen will leverage its Quantidex NGS product platform and Illumina's FDA-cleared MiSeqDx instrument to develop companion diagnostics.

The assay improves upon other tests by attaining a sensitivity of MR4.7 while it allows direct reporting on the IS, Asuragen said.

Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.

A study comparing DNA extracted from standardized blocks of FFPE showed variability among experienced molecular pathology labs.

NEW YORK (GenomeWeb) — Scientists from Asuragen and the New York Institute for Basic Research in Development Disabilities have published research that they claim provides the most compelling evidence to date for a relationship between AGG sequence interruptions and the risk of triplet repeat expa

NEW YORK (GenomeWeb) — Janssen Diagnostics said last week that it is now offering research services on its Cellsearch system for circulating tumor cell preparation in conjunction with Asuragen's SuraSeq next-generation sequencing cancer panels.

NEW YORK (GenomeWeb) – Janssen Diagnostics is now offering next-generation sequencing cancer panels from Asuragen to its research customers, expanding its services in rare cell detection, the company said today.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.